• 1
    Greenlee R, Hill-Harmon M, Murray T, Thum M. Cancer statistics. Cancer J Clin. 2001; 51: 1536.
  • 2
    Chow W, Devesa S, Joseph J. Epidemiology of renal cell carcinoma. In: VogelzangNJ, ScardinoPT, ShipleyWU, CoffeyDS, editors. Comprehensive textbook of genitourinary oncology, 2nd ed. Philadelphia: Lippincott Williams and Wilkins, 2000: 10101100.
  • 3
    Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17: 25302540.
  • 4
    Vogelzang NJ, Stadler WM. Kidney cancer. Lancet. 1998; 352: 16911696.
  • 5
    Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000; 163: 408417.
  • 6
    Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol. 1995; 22: 4260.
  • 7
    Kish JA, Wolf M, Crawford ED, et al. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer. 1994; 74: 916919.
  • 8
    Schilsky R. Antimetabolites. In: PerryMC, editor. The chemotherapy sourcebook. Philadelphia: Williams and Wilkins, 1992: 301317.
  • 9
    Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991; 51: 61106117.
  • 10
    Ren Q, Kao V, Grem JL. Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2′-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res. 1998; 4: 28112818.
  • 11
    Rini BI, Vogelzang NJ, Dumas MC, Wade JL III, Taber DA, Stadler WM. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. 2000; 18: 24192426.
  • 12
    Eisen T, Boshoff C, Mak I, et al. Continuous low dose thalidomide: a Phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer. 2000; 82: 812817.
  • 13
    D'Amato R, Loughnan M, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994; 91: 40824085.
  • 14
    Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999; 59: 728733.
  • 15
    Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 1992; 52: 67026704.
  • 16
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205216.
  • 17
    Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med. 1990; 112: 423428.
  • 18
    Levine M, Hirsh J, Gent M, et al. Double-blind randomized trial of a very-low-dose warfarin for prevention of thromboembolism in Stage IV breast cancer. Lancet. 1994; 343: 886889.
  • 19
    Simon R. Optimal two-stage designs for Phase II clinical trials. Control Clin Trials. 1989; 10: 110.
  • 20
    Gradishar WJ, Vokes EE. 5-Fluorouracil cardiotoxicity: a critical review. Ann Oncol. 1990; 1: 409414.
  • 21
    Rezkalla S, Kloner RA, Ensley J, et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol. 1989; 7: 509514.
  • 22
    Ensley JF, Patel B, Kloner R, Kish JA, Wynne J, al-Sarraf M. The clinical syndrome of 5-fluorouracil cardiotoxicity. Invest New Drugs. 1989; 7: 101109.
  • 23
    Falcini F, Generini S, Pignone A, et al. Are angiotensin converting enzyme and von Willebrand factor circulating levels useful surrogate parameters to monitor disease activity in Kawasaki disease? Endothelium. 1999; 6: 209215.
  • 24
    Cid MC, Monteagudo J, Oristrell J, et al. von Willebrand factor in the outcome of temporal arteritis. Ann Rheum Dis. 1996; 55: 927930.
  • 25
    Direskeneli H, Buchanan NM, Khamashta MA, Keser G, D'Cruz D, Hughes GR. Markers of vascular damage in lupus pregnancy. Clin Exp Rheumatol. 1997; 15: 535539.
  • 26
    Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999; 341: 15651571.
  • 27
    Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol. 1996; 35: 969979.
  • 28
    Ryan C, Vogelzang N, Stadler W. A phase II trial of intravenous gemcitabine and 5-flourouracil with subcutaneous interleukin-2 and interferon-α in patients with metastatic renal cell carcinoma. Cancer. 2002; 94: 26022609.
  • 29
    George CM, Vogelzang NJ, Rini BI, Geoffroy FJ, Kollipara P, Stadler WM. A Phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Ann Oncol. 2002; 13: 116120.
  • 30
    Mani S, Vogelzang NJ, Bertucci D, Stadler WM, Schilsky RL, Ratain MJ. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001; 92: 15671576.
  • 31
    Escudier B, Lassau N, Couanet D, et al. Phase II trial of thalidomide in renal cell carcinoma (abstract 718). Proc Am Soc Clin Oncol. 2001; 20: 180a.
  • 32
    Li Z, Amato R, Papandreaou C, et al. Phase II study of thalidomide for patients with metastatic renal cell carcinoma (MRCC) progressing after interleukin-2 (IL-2) based therapy (abstract 717). Proc Am Soc Clin Oncol. 2001; 20: 180a.
  • 33
    Vuky J, Berg W, Yu R, et al. Phase II trial of thalidomide in patients with metastatic renal cell carcinoma (RCC) (abstract 1056). Proc Am Soc Clin Oncol. 2001; 20: 365a.
  • 34
    Novik Y, Dutcher J, Larkin M, Wiernik P. Phase II study of thalidomide(T) in advanced refractory metastatic renal cell cancer (MRCC): a single institution experience (abstract 1057). Proc Am Soc Clin Oncol. 2001; 20: 265a.
  • 35
    Nathan P, Walker D, Bridle H, Ross P, Stevenson A, Lee S. A Phase II study investigating the use of thalidomide in conjunction with interferon in patients with metastatic renal cell carcinoma (abstract 1058). Proc Am Soc Clin Oncol. 2001; 20: 265a.
  • 36
    Benett CL, Schumock GT, DeSai AA, et al. Thalidomide associated deep vein thrombosis and pulmonary emboli. Am J Med. In press.
  • 37
    Fine H, Maher E, Wen P, Batchelor T, Viscosi E, Figg W. Phase II trial of thalidomide and BCNU in recurrent high-grade gliomas (abstract 218). Proc Am Soc Clin Oncol. 2001; 20: 55a.
  • 38
    Osman K, Comenzo R, Rajkumar S. Deep venous thrombosis and thalidomide therapy for multiple myeloma [letter]. N Engl J Med. 2001; 344: 19511952.
  • 39
    Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001; 98: 16141615.
  • 40
    Sweeney JD, Killion KM, Pruet CF, Spaulding MB. von Willebrand factor in head and neck cancer. Cancer. 1990; 66: 23872389.
  • 41
    Green D, Maliekel K, Sushko E, Akhtar R, Soff GA. Activated-protein-C resistance in cancer patients. Haemostasis. 1997; 27: 112118.
  • 42
    Moake JL, McPherson PD. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Am J Med. 1989; 87: 9N15N.
  • 43
    Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med. 1998; 128: 541544.